Investor Presentation First Nine Months of 2022
61
Investor presentation First nine months of 2022
Novo NordiskⓇ
Large opportunity for activating more people with obesity to
seek treatment and increasing the number of prescribers
ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg
75%
WegovyⓇ patient characteristics in the US
38%
81%
38.8
of patients new to anti-
obesity medication¹
of patients are female
Average BMI
of patients have ≥3 co-
morbidities
Of the people with overweight or obesity in the US, almost 90% have a weight-related comorbidity
BMI
140
(million of people)
27-30 30-35 35-40
(43) (52)
≥40
(25) (20)
Total
(140)
No obesity-related comorbidity²
7
6
2
2
17
million people with a
BMI > 27
Any obesity-related comorbidity
Hereof metabolic syndrome³
36
46
23
18
123
21
26
14
12
72
1 Patients new to anti-obesity medication reflect source of business, where 75% of patients starting WegovyⓇ are naïve to anti-obesity medication treatment and 25% have either switched from or restarted anti-obesity treatment, IQVIA Feb. 2022;
2 Individuals without any of the following obesity related conditions: T2DM, Pre-diabetes, NASH, NAFLD, obstructive sleep apnea, osteoarthritis, PCOS, ASCVD, Heart failure, asthma, urinary incontinence, hypertension, chronic kidney disease stg. 3 or 4,
musculoskeletal pain, dyslipideamia, metabolic syndrome; 3 Metabolic syndrome defined as two or more of dyslipidaemia; hypertension; prediabetes OR type II diabetes
Source: Novo Nordisk real world research; National Health And Examination Survey (NHANES) cycles 2015-2016 and 2017-2018View entire presentation